There is no uplisting because there is no license, the financials are not even audited which he has been misleading people since the beginning of 2014. Wake up people this was only a nice flip back in 2014 when they were pumping PRs left and right.
They fell on getting the supplements going,
They fell on getting the MMJ license, and now they are pumping a story of on a can of water with sugar and caffeine.
I guess we all know where all this is headed, mo money for BILL. Oh! And remember they have no clarify why they increased the A/S, how much is the so called HEMP TECHNOLOGIES LTD IS making every Q, and so on. Maybe he needs another condo in New York paid for by FITX share holders.
This is the problem with most mid stage bios, it takes a couple of years to attract institutional buyers. The science is good and until we don't get some top line results on the current studies RXII is the hands of the shorts thanks in part to financier TANG. Unless something really good happens I see this one trading at current levels until mid October.
No need to educate you on math, if by now you don't know how to multiply 71 mil by .08 average there is no hope for you. Do your DD, you will find he bought a penthouse in New York. The pps says it all. That is what the market thinks FITX is worth, thanks to BILL.
Poor soul, I guess you have not done your DD on bill and all he bought with the 71 million shares plus he sold. That is why he keeps on pumping hope to all investors. But good look, you will need it.
First supplements and it didn't work, second #$%$ and it didn't work, now energy drinks and that is looking like is not going to work, after that I guess is candy, bread, water or whatever else old BILL thinks to lie and get more money for his own gain.
Audited financials never happened as he said back in mid 2014,
5W PR dropped them from their client list for misleading their investors and public,
The si call merger with a made up group of companies never happened,
The CEN spin off obviously is BS since without a MMJ license this company has no value,
$75 thousand dollars down the drain every month for a lease paid to his cousin on a pice of land that is not being used,
The second property was supposedly bought, but we don't know if the deed is on Bill' name or CEN's name,
I don't know should I keep going, I guess by now you should get my point.
I have already explained it to you twice, I third time is just a waste of my time. Go back two years and do your DD, and then come back to me. In reality you are using something positive to make it look bad. The FACT is that without a R/S RXII would not be a company trading on the NASDAQ. FACT check for everybody, that R/S was done when RXII was trading in the OTC market.
Curtis Lockshin, Ph.D., Chairman of Corporate Governance
Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. He currently serves as the CEO of Guardum Pharmaceuticals, LLC in Lexington, MA, a wholly owned US subsidiary of OJSC Pharmsynthez which is headquartered in St. Petersburg, Russia. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.
An ignorant comment about the reverse split, well then again you could be suffering from brain damage because you keep repeating the same over and over. Ok JR, I will explain it with play-doh this time: a reverse split was done back in 2013 to be able to get out of the OTC and uplist on the NASDAQ.
And here is an example of why, big pharma is investing heavily in RNA.
You ARE an ignorant investor if you keep going back and forth about the reverse split. Yes a reverse split was done in 2013 to uplist to the NASDAQ. All credible companies that were in the OTC have to go through a R/S in order to uplist on the NASDAQ OR AMEX. Laughable.